Next-generation sequencing of the TET2 gene in 355 MDS and CMMLpatients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

Blood

Volumn 116, Issue 19, 2010, Pages 3923-3932

  Smith, Alexander E ^a   Mohamedali, Azim M ^a   Kulasekararaj, Austin ^a   Lim, ZiYi ^a   Gäken, Joop ^a   Lea, Nicholas C ^a   Przychodzen, Bartlomiej ^a   Mian, Syed A ^a   Nasser, Erick E ^a   Shooter, Claire ^a   Westwood, Nigel B ^a   Strupp, Corinna ^b   Gattermann, Norbert ^b   Maciejewski, Jaroslaw P ^c   Germing, Ulrich ^b   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW CELL; CD34 SELECTION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLONE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HAPLOTYPE; HETEROZYGOSITY; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TET2 GENE; WORLD HEALTH ORGANIZATION;

EID: 78149454504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-274704     Document Type: Article

References (35)

1. Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J. 2003;4(5):303-309.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
3. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-4851.
4. Nolte F, Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol. 2008;87(10):777-795.
5. Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112(4):965-974.
6. Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110(9):3365-3373. (Pubitemid 350106331)
7. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403-6410.
8. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS-, MDS/MPD-, and MDS-derived AML. Blood. 2008;111(3):1534-1542. (Pubitemid 351213443)
9. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. NEJM. 2009;360(22):2289-2301.
10. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676-1681.
11. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
12. Mohamedali AM, Smith AE, Gaken J, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol. 2009;27(24):4002-4006.
13. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN, and AML. Leukemia. 2009; 23(7):1343-1345.
14. Ganetzky RD, Jankowska AM, Prince C, Advani A, Saunthararajah Y, Maciejewski JP. TET2 mutation status is associated with distinct hypermethylation patterns; a marker of epigenetic instability? Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 215.
15. Szpurka H, Jankowska AM, Ng KP, Clevenger JR, Saunthararajah Y, Maciejewski JP. Involvement of TET2 in regulation of epigenetic silencing in MDS and related myeloid malignancies. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 2908.
16. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002;62(14):4075-4080. (Pubitemid 34791077)
17. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17(3):637-641. (Pubitemid 36395661)
18. Tahiliani M, Koh KP, Shen YH, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.
19. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2207.
20. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447-452.
21. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2009;115(14):2891-2900.
22. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-2890.
23. Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285-3291.
24. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
25. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn. 2007;9(1):42-46. (Pubitemid 47322012)
26. Mullighan CG. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet. 2009;41(7):766-767.
27. Delhommeau F, Dupont S, James C, et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre-JAK2 V617F event. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract lba-3.
28. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12(7):852-855. (Pubitemid 44050078)
29. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924-935.
30. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23-28.
31. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731-2739.
32. Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu RV, Maciejewski JP. Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia. 2008;22(3):551-558. (Pubitemid 351386725)
33. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
34. Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
35. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61(8):3230-3239.